Mission
IMAXIO is a biotech company specialized in vaccinology and in human leptospirosis prophylaxis.
Often called "rate disease" or "swineherd's disease", this zoonosis is an emerging public health issue in Europe and especially in France.
In 2014-2016 leptospirosis cases in metropolitan France doubled compared to previous years with an average of 600 cases/year. 54% of leptospirosis occurring in working people would be caused by occupational exposure.
IMAXIO engages with occupational healthcare professionals and health authorities to prevent and to increase awareness about leptospirosis risks at work with, for example in France, its dedicated website:
www.leptospirose-prevention.fr
Management team
Dr. Christian PRADEYROL, Chairman of the Board and CEO
Dr. Christian PRADEYROL is Chairman of the Board of IMAXIO and CEO. Since 2007, Dr. PRADEYROL is Executive Chairman and founder of Pradeyrol Développement, a family office actively investing in new technologies. With participations in a decade of biotech in France and in the US, Pradeyrol Développement is highly interested in immunology and preventive medicines both in vaccines and drugs and diagnostics.
Mr. Alexandre LE VERT, Board Member
Alexandre LE VERT is Board Member of IMAXIO and is the Chairman and Co-founder of OSIVAX. Alexandre started his career as a research scientist at Harvard University and Institut Pasteur (2001 – 2003). He then became Marketing Manager and Sales Director at BMS France (2003-2008), before spending two years in the Paris office of the Boston Consulting Group as a consultant (2009-2011), and 6 years as the CEO of Imaxio and Investment Director for Pradeyrol Développement (2011-2017). Alexandre is a Board Member of several biotech companies in France and in the US and a co-founder of an Asian based e-commerce company. Alexandre LE VERT graduated from Ecole Polytechnique (MS) (Palaiseau, France) and Harvard University (MA, USA).
Mr. Sylvain LANDON, Chief Operating & Financial Officer
Sylvain LANDON is COO/CFO of IMAXIO since January 2014 and has been a Financial Director and Advisor of Pradeyrol Développement since 2014. He started his career as Reporting & Consolidation team member at bioMérieux in France (2007-2008). He was then promoted to the role of Financial Controller and Director at bioMérieux South Africa in the context of a new subsidiary creation (2008-2013). Sylvain is Board member of several companies of Pradeyrol Recherche et Développement and funder of a South African based company specializing in medical solutions. Sylvain LANDON graduated from IAE Saint Etienne (France), he holds a Master in Accounting, Control, Audit and the French National Chartered Accounting diploma (DESCF, pre-CA), both completed in 2006/2007.
Dr. Valérie HUERTAS, Qualified Person, Pharmaceutical Affairs Director and Deputy CEO
Dr. Valérie HUERTAS is Qualified Person, Pharmaceutical Affairs Director and Deputy CEO of IMAXIO. She has a significant experience in regulatory development, quality assurance, GMP manufacturing and pharmaceutical affairs in various companies before reaching IMAXIO, such as Guerbet, Septodont, Lynapharm, Ebewe, Iphym and Juvisé. She is graduated from the University of Pharmacy of Reims, the University of Paris-Saclay Regulatory Affairs Master, the ESCP Quality Management Master.
Dr. Christian PRADEYROL is Chairman of the Board of IMAXIO and CEO. Since 2007, Dr. PRADEYROL is Executive Chairman and founder of Pradeyrol Développement, a family office actively investing in new technologies. With participations in a decade of biotech in France and in the US, Pradeyrol Développement is highly interested in immunology and preventive medicines both in vaccines and drugs and diagnostics.
Mr. Alexandre LE VERT, Board Member
Alexandre LE VERT is Board Member of IMAXIO and is the Chairman and Co-founder of OSIVAX. Alexandre started his career as a research scientist at Harvard University and Institut Pasteur (2001 – 2003). He then became Marketing Manager and Sales Director at BMS France (2003-2008), before spending two years in the Paris office of the Boston Consulting Group as a consultant (2009-2011), and 6 years as the CEO of Imaxio and Investment Director for Pradeyrol Développement (2011-2017). Alexandre is a Board Member of several biotech companies in France and in the US and a co-founder of an Asian based e-commerce company. Alexandre LE VERT graduated from Ecole Polytechnique (MS) (Palaiseau, France) and Harvard University (MA, USA).
Mr. Sylvain LANDON, Chief Operating & Financial Officer
Sylvain LANDON is COO/CFO of IMAXIO since January 2014 and has been a Financial Director and Advisor of Pradeyrol Développement since 2014. He started his career as Reporting & Consolidation team member at bioMérieux in France (2007-2008). He was then promoted to the role of Financial Controller and Director at bioMérieux South Africa in the context of a new subsidiary creation (2008-2013). Sylvain is Board member of several companies of Pradeyrol Recherche et Développement and funder of a South African based company specializing in medical solutions. Sylvain LANDON graduated from IAE Saint Etienne (France), he holds a Master in Accounting, Control, Audit and the French National Chartered Accounting diploma (DESCF, pre-CA), both completed in 2006/2007.
Dr. Valérie HUERTAS, Qualified Person, Pharmaceutical Affairs Director and Deputy CEO
Dr. Valérie HUERTAS is Qualified Person, Pharmaceutical Affairs Director and Deputy CEO of IMAXIO. She has a significant experience in regulatory development, quality assurance, GMP manufacturing and pharmaceutical affairs in various companies before reaching IMAXIO, such as Guerbet, Septodont, Lynapharm, Ebewe, Iphym and Juvisé. She is graduated from the University of Pharmacy of Reims, the University of Paris-Saclay Regulatory Affairs Master, the ESCP Quality Management Master.
Partners
